MD Anderson Cancer Center
CA-125 Change Over Time Shows Promise for Early Detection of Ovarian Cancer – CNL
Evaluating its change over time, CA-125, the protein long-recognized for predicting ovarian cancer recurrence, now sh ow promise as a screening tool for early stage disease. Karen Lu, M.D., and Robert Bast, M.D., discuss their study highlighted at the year’s American Society of Clinical Oncology (ASCO) conference.
This audio is avaliable in a Flash version only and requires an updated Flash player. Please update your Flash player or watch on a device which supports Flash. Flash Player Help . For additional recordings, please visit our online search for additional media resources.

Title: CA-125 Change Over Time Shows Promise for Early Detection of Ovarian Cancer – CNL
Summary: Evaluating its change over time, CA-125, the protein long-recognized for predicting ovarian cancer recurrence, now sh ow promise as a screening tool for early stage disease. Karen Lu, M.D., and Robert Bast, M.D., discuss their study highlighted at the year’s American Society of Clinical Oncology (ASCO) conference.
Keywords: M. D. Anderson, MD Anderson,ovarian cancer, robert bast, karen lu, CA-125, blood test, screening, gynecologic oncology, cancer
Transcript: